Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)
Crossref DOI link: https://doi.org/10.1007/s11523-014-0337-6
Published Online: 2014-09-19
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Donini, M.
,
Buti, S.
Lazzarelli, S.
Bozzetti, R.
Rivoltini, L.
Camisaschi, C.
Castelli, C.
Bearz, A.
Simonelli, C.
Lo Re, G.
Mattioli, R.
Caminiti, C.
Passalacqua, R.
Text and Data Mining valid from 2014-09-19